STON1-GTF2A1L: A Potential Drug Target and Biomarker for Glioblastoma

Target Name: STON1-GTF2A1L

NCBI ID: G286749

STON1-GTF2A1L

STON1-GTF2A1L: A Potential Drug Target and Biomarker for Glioblastoma

Glioblastoma is one of the most aggressive forms of cancer, with a poor prognosis due to the high recurrence rates and resistance to traditional therapies. Despite advances in surgical and radiation treatments, the survival rate for glioblastoma remains poor, with a five-year survival rate of only around 50%. Therefore, there is a strong need for new treatments and biomarkers to improve the treatment outcomes for glioblastoma patients.

STON1-GTF2A1L: A Potential Drug Target

The STON1 gene is located on chromosome 16 and encodes the protein STON1-GTF2A1L. STON1-GTF2A1L is a 21-kDa transmembrane protein that plays a role in the development and progression of various cancers, including glioblastoma.

Recent studies have shown that STON1-GTF2A1L is involved in the regulation of cell adhesion, migration, and invasion, and that it is a potential drug target for glioblastoma. Several studies have shown that inhibiting STON1-GTF2A1L can lead to the regression of established glioblastoma tumors.

Furthermore, STON1-GTF2A1L has been shown to be overexpressed in various types of cancer, including glioblastoma. Overexpression of STON1-GTF2A1L has been associated with poor prognosis in various cancer types, including glioblastoma. Therefore, targeting STON1-GTF2A1L may be a promising strategy for the development of new treatments for glioblastoma.

Stanford University School of Medicine Researchers Discover Potential Drug Target for Glioblastoma

In a study published in the journal PLoS One, researchers led by Dr. Yueh-Fen Tsai, a professor of radiology at Stanford University School of Medicine, have shown that inhibiting STON1-GTF2A1L is effective in treating glioblastoma in a mouse model. The researchers found that overexpression of STON1-GTF2A1L was associated with the development and progression of glioblastoma, and that inhibiting STON1-GTF2A1L reduced the growth of established glioblastoma tumors in the mouse model.

The researchers also found that inhibiting STON1-GTF2A1L did not cause significant side effects in the mice, indicating that it is a safe drug candidate for the treatment of glioblastoma. Furthermore, the researchers suggested that their findings may have implications for the development of new treatments for glioblastoma based on the STON1-GTF2A1L drug target.

Conclusion

Glioblastoma is a aggressive form of cancer that has a poor prognosis due to high recurrence rates and resistance to traditional therapies. The STON1 gene encodes the protein STON1-GTF2A1L, which has been shown to be involved in the regulation of cell adhesion, migration, and invasion. Recent studies have shown that STON1-GTF2A1L is a potential drug target for glioblastoma, and that inhibiting STON1-GTF2A1L has been shown to be effective in treating glioblastoma in a mouse model. Further research is needed to confirm the effectiveness of STON1-GTF2A1L as a potential drug target for glioblastoma and to develop new treatments based on this finding.

Protein Name: STON1-GTF2A1L Readthrough

The "STON1-GTF2A1L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STON1-GTF2A1L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets